Press Releases | Page 22 of 42

Behind the Study: HER3: A Vital Target in Cancer Treatment

October 12, 2023

Dr. Omkar Desai from the Department of Surgery at Case Western Reserve University and University Hospitals Cleveland Medical Center, describes a research perspective he co-authored with Dr. Rui Wang that… read more

Oncotarget

Suppression of Cancer Stemness and Drug Resistance via BRAF/EGFR/MEK Inhibition in Colorectal Cancer Cells

October 11, 2023

“[...] our approach enables mechanistic studies of drug resistance with 3D cultures of primary cancer cells to develop and test treatments that suppress cancer [...].” BUFFALO, NY- October 11, 2023… read more

Figure 1: (A) Canonical STAT3 activation pathway. (B) WP1066 and TTI-101, examples of small molecule STAT3 inhibitors that are cell penetrant.

Oncotarget

STAT3 as a Target in H3K27M-mutant DMGs

October 9, 2023

“Children diagnosed with these tumors have [...] a median survival of approximately 12 months.” BUFFALO, NY- October 9, 2023 – A new editorial perspective was published in Oncotarget's Volume 14… read more

Figure 2: UGDH’s roles in cancer biology.

Oncotarget

UGDH in Clinical Oncology and Cancer Biology

October 4, 2023

“Given the potential challenges of directly inhibiting UGDH, therapeutic strategies may extend to targeting downstream pathways and upstream substrates.” BUFFALO, NY- October 4, 2023 – A new review paper was… read more

Oncotarget

An Ancient Anti-cancer Mechanism: DISE

October 3, 2023

“DISE is effective against all cancers we tested.” BUFFALO, NY- October 3, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on September 25, 2023, entitled, “DISE,… read more

Oncotarget

Reassessing COVID-19 Precautions in 2023

September 27, 2023

“The balance between appropriate precautions and the harm of social isolation always requires a thorough appraisal.” BUFFALO, NY- September 27, 2023 – A new editorial paper was published in Oncotarget's… read more